RECOMBINANT PSEUDO ADENOVIRAL PARTICLE PRODUCING MODIFIED NANOANTIBODIES RECOGNISING MYCOPLASM MHOMINIS, BASED PHARMACEUTICAL COMPOSITION AND METHOD FOR USING IT FOR MYCOPLASMOSIS THERAPY Russian patent published in 2015 - IPC C12N7/01 C12N15/11 C07K16/12 A61K39/02 

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to molecular immunology, biotechnology and medicine. A pre-modified sequence of an antibody gene is the nucleotide sequence SEQ ID 1. The created recombinant pseudo adenoviral particle activates a complement system of the mammalian immune system. The pharmaceutical composition represents the recombinant pseudo adenoviral particles according to the declared invention, and a pharmaceutically acceptable carrier; when administered into a mammalian organism, it activates the complement system and suppresses mycoplasm M. hominis. A method for mycoplasm M. hominis therapy is implemented by administering a therapeutically effective amount of the created pharmaceutical composition into a mammal in need thereof. The pharmaceutical composition is administered by intravenous injections.

EFFECT: created is the recombinant pseudo adenoviral particle based on human being adenovirus genome of serotype 5 containing an expressing cassette with gene insertion of a modified chimeric nanoantibody binding to mycoplasm M hominis, a nucleotide sequence of which is pre-modified by attaching the effector Fc-fragment of immunoglobulin G.

5 cl, 6 dwg, 2 tbl, 6 ex